AstraZeneca Loses Final Bid For Additional Seroquel Exclusivity
This article was originally published in The Pink Sheet Daily
Executive Summary
An appeals court finds FDA acted reasonably in denying AstraZeneca’s request for three years of marketing exclusivity for data it submitted for inclusion in Seroquel labeling.